5,420 reports of this reaction
1.7% of all DICLOFENAC SODIUM 1% reports
#10 most reported adverse reaction
GLOSSODYNIA is the #10 most commonly reported adverse reaction for DICLOFENAC SODIUM 1%, manufactured by Aurobindo Pharma Limited. There are 5,420 FDA adverse event reports linking DICLOFENAC SODIUM 1% to GLOSSODYNIA. This represents approximately 1.7% of all 323,575 adverse event reports for this drug.
Patients taking DICLOFENAC SODIUM 1% who experience glossodynia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GLOSSODYNIA is a less commonly reported adverse event for DICLOFENAC SODIUM 1%, but still significant enough to appear in the safety profile.
In addition to glossodynia, the following adverse reactions have been reported for DICLOFENAC SODIUM 1%:
The following drugs have also been linked to glossodynia in FDA adverse event reports:
GLOSSODYNIA has been reported as an adverse event in 5,420 FDA reports for DICLOFENAC SODIUM 1%. This does not prove causation, but indicates an association observed in post-market surveillance data.
GLOSSODYNIA accounts for approximately 1.7% of all adverse event reports for DICLOFENAC SODIUM 1%, making it a notable side effect.
If you experience glossodynia while taking DICLOFENAC SODIUM 1%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.